|
|
News Breaks | | | | February 8, 2013 | | 08:04 EDT |  | STJ | St. Jude says RESPECT data show device group patients had fewer, smaller strokes
St. Jude Medical announced the presentation of additional data from its landmark RESPECT trial at the American Stroke Association’s International Stroke Conference 2013 in Honolulu. The RESPECT trial evaluated whether closing an opening in the heart, called a patent foramen ovale or PFO, with the AMPLATZER PFO Occluder lowered the patient’s risk of having another stroke. The purpose of analyzing these additional data from the RESPECT trial was to determine if patients in the device and medical therapy group suffered different types of recurrent strokes, and to identify the potential origin of the strokes. The results confirm that patients with a device in place were less likely to suffer another stroke and patients in the medical group experienced larger strokes. PFO closure with the AMPLATZER PFO Occluder demonstrates clinical evidence of risk reduction and is an important option for the prevention of recurrent stroke in carefully selected patients over conventional medical management alone. | |
|
News For STJ From The Last 14 Days Check below for free stories on STJ the last two weeks. |
|
|
| May 23, 2013 | | 05:44 EDT | | STJ | St. Jude Medical study of EnligHTN shows sustained blood pressure reduction
St. Jude Medical announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. Patients enrolled in the EnligHTN I trial had an average blood pressure of 176 / 96 mmHg and patients were drug-resistant, meaning their blood pressure could not be controlled through medication. At one year, patients treated with the EnligHTN Renal Denervation System experienced an average systolic blood pressure reduction of 27 mmHg points when measured in an office setting. | | | May 20, 2013 | | 11:12 EDT | | STJ | St. Jude Medical to evaluate defibrilator lead related to reported death
 Subscribe for More Information | | | May 16, 2013 | | 08:05 EDT | | STJ | St. Jude Medical's 3-D vessel reconstruction system approved in Europe
St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform. | | | May 14, 2013 | | 08:09 EDT | | STJ | St. Jude Medical announces first patient enrolled in EnligHTN III study
Subscribe for More Information | |
|
|
|
|
|
|
